Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $124.7 million.

  • 10x Genomics' Shares Outstanding (Weighted Average) rose 356.85% to $124.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $124.7 million, marking a year-over-year increase of 356.85%. This contributed to the annual value of $124.7 million for FY2025, which is 356.85% up from last year.
  • Latest data reveals that 10x Genomics reported Shares Outstanding (Weighted Average) of $124.7 million as of Q4 2025, which was up 356.85% from $125.5 million recorded in Q3 2025.
  • 10x Genomics' Shares Outstanding (Weighted Average)'s 5-year high stood at $125.5 million during Q3 2025, with a 5-year trough of $108.7 million in Q1 2021.
  • Over the past 5 years, 10x Genomics' median Shares Outstanding (Weighted Average) value was $116.9 million (recorded in 2023), while the average stood at $116.9 million.
  • Per our database at Business Quant, 10x Genomics' Shares Outstanding (Weighted Average) skyrocketed by 1227.41% in 2021 and then surged by 234.91% in 2023.
  • 10x Genomics' Shares Outstanding (Weighted Average) (Quarter) stood at $110.3 million in 2021, then rose by 3.18% to $113.9 million in 2022, then grew by 2.9% to $117.2 million in 2023, then increased by 2.81% to $120.5 million in 2024, then increased by 3.57% to $124.7 million in 2025.
  • Its last three reported values are $124.7 million in Q4 2025, $125.5 million for Q3 2025, and $123.8 million during Q2 2025.